iSpecimen (ISPC) AI Stock Analysis

• Market Cap: $4.43M
• Dividend Yield: N/A
• Average Volume (3M): 986.32K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.45
• Revenue Growth: -43.77%
• EPS Growth: 55.78%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.42
• Shares Outstanding: 5,539,345
• 10 Day Avg. Volume: 1,897,072
• 30 Day Avg. Volume: 986,316
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 0.36
• Enterprise Value/Gross Profit: 1.11
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: $1.00
• Price Target Upside: 35.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: $1.00 ▲(35.14% Upside)

The overall stock score is primarily influenced by weak financial performance, with ongoing losses and cash flow issues. Technical analysis provides mixed signals, and valuation remains unattractive due to negative earnings. While recent corporate events show strategic progress, the Nasdaq non-compliance notice is a significant concern.

iSpecimen Business Overview & Revenue Model

Company Description

iSpecimen Inc. (ISPC) is a technology-driven company operating in the healthcare sector, specializing in the procurement and distribution of human biospecimens. The company provides a centralized marketplace that connects researchers with a diverse network of healthcare providers and biobanks. iSpecimen's platform streamlines the process of sourcing, managing, and delivering biological samples, which are critical for advancing medical research and development.

How the Company Makes Money

iSpecimen makes money primarily through its marketplace platform, which facilitates the procurement of human biospecimens for research purposes. The company generates revenue by charging fees for matching researchers with biospecimen suppliers and for providing logistical services in the collection and delivery of specimens. Additionally, iSpecimen may earn through subscription or transaction-based models with its partners in the healthcare and biobanking sectors. Strategic partnerships with healthcare institutions and biobanks further enhance its revenue-generating capabilities by expanding its access to a wide range of sample types and increasing the platform's attractiveness to researchers.

iSpecimen Financial Statement Overview

Summary

iSpecimen faces significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite some improvements in the balance sheet with reduced debt levels and improved equity ratios, the company's financial health remains weak, with persistent net losses and cash flow deficits.

Income Statement

The company has shown a declining trend in revenue and profitability. Gross Profit Margin decreased from 52.8% in 2020 to 42.9% in 2024. Net Profit Margins remain negative, with worsening EBIT and EBITDA margins, indicating operational inefficiency. Revenue has been declining from $11.13 million in 2021 to $9.29 million in 2024, showcasing negative growth.

Balance Sheet

The balance sheet reflects a relatively high level of debt with a Debt-to-Equity Ratio of 0.09 in 2024, reduced from previous years. However, the negative equity in prior years raises concerns about financial stability. The equity ratio improved to 35.4% in 2024 from negative figures in earlier years, indicating some improvement in financial health.

Cash Flow

The company has consistently negative operating and free cash flows, with a significant cash burn. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash. Although free cash flow improved slightly in 2024 compared to previous years, it remains negative, indicating continued challenges in liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.91M	9.29M	9.93M	10.40M	11.14M	8.18M
Gross Profit	1.93M	3.99M	5.11M	5.65M	5.89M	4.60M
EBITDA	-8.00M	-12.73M	-9.10M	-8.80M	-5.86M	-1.74M
Net Income	-10.19M	-12.50M	-11.10M	-9.04M	-10.02M	-6.76M
Balance Sheet
Total Assets	6.03M	9.35M	15.82M	24.62M	35.72M	6.21M
Cash, Cash Equivalents and Short-Term Investments	588.77K	1.88M	5.01M	15.31M	27.74M	695.91K
Total Debt	287.88K	312.17K	196.24K	185.85K	3.42M	12.77M
Total Liabilities	5.41M	6.04M	6.08M	4.31M	5.93M	33.49M
Stockholders Equity	621.97K	3.31M	9.74M	20.31M	29.79M	-27.28M
Cash Flow
Free Cash Flow	-6.19M	-8.30M	-10.55M	-9.01M	-11.71M	-1.39M
Operating Cash Flow	-5.94M	-8.26M	-5.81M	-5.82M	-10.67M	-288.38K
Investing Cash Flow	-253.47K	1.98M	-7.23M	-3.19M	-1.04M	-1.10M
Financing Cash Flow	4.63M	5.82M	70.89K	-3.42M	38.75M	2.03M

iSpecimen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.08, and below the 200-day MA of 1.85, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 7.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.

iSpecimen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
AWHL	48 Neutral	$14.69M	―		―	4.10%	67.32%
ISPC	47 Neutral	$4.43M	―	-303.74%	―	-43.77%	55.78%
APDN	42 Neutral	$4.33M	―	-130.75%	―	-2.96%	89.71%
NDRA	34 Underperform	$3.08M	―	-167.48%	―	―	77.66%
CHEK	26 Underperform	$3.70M	―	-74.17%	―	―	―
BGLC	―	$10.04M	―	-34.37%	―	―	―

iSpecimen Corporate Events

iSpecimen Completes Milestone 1 in Digital Transformation

On August 21, 2025, iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program, which involved the installation of the Salestack platform and the provisioning of modern infrastructure. This milestone enhances the iSpecimen Marketplace® with a cloud-native architecture, improving reliability, security, and innovation capabilities, and sets the stage for the next phase of integration aimed at achieving end-to-end operational efficiency.

iSpecimen Announces Strategic Digital Asset Initiative

On August 7, 2025, iSpecimen Inc. announced a strategic initiative to integrate digital assets into its business model by establishing a corporate treasury reserve of up to $200 million based on the Solana blockchain ecosystem. This move, supported by WestPark Capital and BlockArrow, aims to enhance iSpecimen’s technological leadership in the life sciences by leveraging Solana’s high throughput, low transaction costs, and robust security features, potentially positioning the company as a leader in digital asset adoption and innovation.

iSpecimen Completes $1.75M Private Placement Deal

On July 31, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors, resulting in a private placement of 1,559,828 shares of common stock or pre-funded warrants, generating gross proceeds of approximately $1.75 million. The placement, which closed on August 4, 2025, was conducted in compliance with Nasdaq rules and involved WestPark Capital, Inc. as the exclusive placement agent. The company plans to allocate $500,000 of the net proceeds for marketing and advertising services, with the remainder used for working capital and general corporate purposes. Additionally, iSpecimen entered into a registration rights agreement to facilitate the resale of shares and a marketing agreement with IR Agency LLC to enhance its visibility in the financial community.

iSpecimen Completes Public Offering to Raise $4 Million

On July 23, 2025, iSpecimen Inc. entered into an underwriting agreement with WestPark Capital, Inc. to sell 5,714,283 securities in an underwritten public offering, closing on July 25, 2025. The offering raised approximately $4 million in gross proceeds, with net proceeds of around $3.53 million, which the company plans to use for marketing, a software purchase, and general corporate purposes. The offering enhances iSpecimen’s financial resources, potentially strengthening its market position and operational capabilities.

iSpecimen Appoints Anthony Lau to Board of Directors

On June 18, 2025, Richard J. Paolone and John L. Brooks III resigned from the Board of Directors of iSpecimen Inc., with no disagreements cited regarding company operations or policies. Subsequently, on June 20, 2025, Anthony Lau was appointed to the Board, bringing extensive experience in corporate governance and financial oversight, which is expected to enhance the company’s governance and oversight capabilities.

iSpecimen Faces Nasdaq Non-Compliance Notice

On June 4, 2025, iSpecimen Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market, as their equity was reported at $1,668,513. The company has 45 days to submit a compliance plan, and if accepted, may receive an extension of up to 180 days to meet the listing criteria, although there is no guarantee of acceptance or compliance.